Restore the GH Axis. Through Your Own Biology.
- CJC-1295 · Ipamorelin · Sermorelin
- Stimulates natural GH, not exogenous HGH
- SubQ Injection · Nightly
Your Pituitary Still Works. We Support the Signal.
Most Commonly Prescribed GH Stack
CJC-1295 / Ipamorelin
GHRH Analogue + Selective Growth Hormone Releasing Peptide
The most commonly prescribed growth hormone peptide combination. CJC-1295 is a GHRH analogue that may extend the GH-releasing hormone signal. Ipamorelin is a selective GHRP that may stimulate GH release without the cortisol and prolactin elevations associated with older peptides in this class. Together they may produce an amplified, natural-pattern GH pulse, supporting recovery, body composition, and sleep quality.
Proposed mechanism: CJC-1295 binds GHRH receptors to extend GH-releasing signal · Ipamorelin binds ghrelin receptors to selectively amplify GH pulse · Combined effect may support sustained natural GH secretion.
- Availability subject to current FDA compounding regulations. Compound status may change. Full regulatory disclosure provided at consultation.
Typical Administration
Subcutaneous injection · 5 nights per week · Before sleep · Patient self-administered following training
Entry GH Protocol
Sermorelin
GHRH 1-29 Analogue
Sermorelin is the first 29 amino acids of endogenous GHRH, a synthetic analogue that may stimulate the pituitary to produce and release growth hormone through the body's own feedback mechanisms. Often used as an introductory GH peptide protocol. Its action is subject to natural negative feedback, which limits the potential for axis suppression.
Proposed mechanism: Binds GHRH receptors on pituitary somatotroph cells · May stimulate GH synthesis and release through endogenous pathways · Subject to normal negative feedback regulation.
- Compounding availability subject to current FDA regulations. Status may change. Full disclosure at consultation.
Typical Administration
Subcutaneous injection · Nightly · Patient self-administered
Why not inject HGH directly? Exogenous human growth hormone bypasses the pituitary entirely, suppressing your body's own GH production over time. Growth hormone secretagogues work upstream through your body's own feedback mechanisms. This difference has meaningful clinical and safety implications that are discussed in detail at consultation.
GH Peptides · Ann Arbor
Sleep Deeper. Recover Faster. From Your Own Biology.
Growth hormone peptide protocols begin with an IGF-1 and GH marker review. Schedule a consultation: we review your baseline data and design the protocol appropriate for your age, health status, and goals.
Medical, Regulatory & Legal Disclosure
General: The information presented on this page is for educational purposes only and does not constitute medical advice. Peptide therapy protocols are individualized medical treatments that require comprehensive clinical evaluation, baseline laboratory testing, and ongoing supervision by a licensed healthcare provider. Individual results vary. Not all individuals are appropriate candidates for peptide therapy.
FDA Regulatory Status: Peptide therapies vary in their FDA regulatory status. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro®) and obesity (Zepbound®); compounded versions are prescribed under applicable compounding pharmacy regulations. PT-141 (Bremelanotide) is FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women; use in men or for other indications constitutes off-label prescribing. Retatrutide is an investigational compound currently in Phase 3 clinical trials and has not received FDA approval for any indication. BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-c, Epithalon, GHK-Cu, Kisspeptin, Selank, and Semax are investigational compounds that are not FDA-approved and whose compounding availability is subject to current FDA bulk drug substances regulations. Availability of specific compounds may change based on evolving regulatory guidance.
Informed Consent: Written informed consent is required for all peptide protocols at Arbour Longevity. Informed consent documentation includes the FDA regulatory status of each compound, available clinical evidence (including the level and quality of that evidence), known and potential risks, available alternatives, and the investigational nature of applicable compounds. No prescription is issued without completed informed consent.
Compounding: Where applicable, peptide compounds are sourced from 503A or 503B registered compounding pharmacies in compliance with applicable federal and state regulations in effect at the time of prescribing. Arbour Longevity does not guarantee the ongoing availability of any specific compound, as availability is subject to FDA regulatory determinations that may change without notice.
No Guarantee of Results: Clinical outcomes described on this website represent potential benefits based on available research and clinical experience. No guarantee of specific results is expressed or implied. Peptide therapy is not a substitute for conventional medical treatment where such treatment is indicated.
Regenerative medicine and aesthetic arts: where science meets the artistry of transformation.
.png)
